Reproductive System – Cannabis and Cannabinoid Research

Reproductive System Research Dashboard

125

Primary Studies

24

Related Studies

149

Total Studies

Clinical Studies

3

Double-blind human trials

5

Clinical human trials

Pre-Clinical Studies

54

Meta-analyses/Reviews

19

Animal studies

43

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 149 studies associated with Reproductive System.

Here is a small sampling of Reproductive System studies by title:


Components of the Reproductive System Research Dashboard

  • Medical conditions associated with Reproductive System
  • Synopsis of cannabis research for Reproductive System
  • Chemotype guidance for Reproductive System
  • Individual study details for Reproductive System

Ready to become a subscriber? Go to our PRICING page.

Select New Organ System

Filter Organ System

Members can filter by the following criteria:

  • Study Type
  • Chemotype
  • Cannabinoids & Endocannabinoids
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Reproductive System

Description of Reproductive System

The reproductive system functions to provide sexual pleasure and to produce offspring. It is made up of sexual organs. In gender typical females: the vagina, uterus, fallopian tubes, ovaries, and mammary glands. In gender typical males: penis, testes, vas deferens, seminal vesicles, and the prostate. In intersex individuals, typical sexual distinctions or biological characteristics may vary.

Reproductive System and ECS-Based Interactions

The endocannabinoid system is increasingly activated at the time of ovulation. More specifically, levels of the endocannabinoid anandamide increase at the time of ovulation. As such cannabinoids may exert influence on the earliest processes of conception and egg implantation in the uterine wall and thus may play a significant role in fertility. For instance, mammalian research discovered that dose-dependent anandamide opens or closes doors relevant to the conception of life itself. That is, low levels of anandamide enhanced egg implantation and higher levels diminish egg implantation and as such may play a dual role (biphasic effect) in the prevention of miscarriage and at the same time may function an early abortifacient. Endocannabinoid receptors are present in parts of both male and female reproductive organs. CB1 receptors have been identified in the ovaries, uterus, and the testes. CB2 receptor sites were identified in cells of ovarian cortex, ovarian medulla, and ovarian follicles. The G-protein coupled receptor 18 has been found in the midpiece of the human spermatozoa.

Reproductive System Medical Specialists

For Females: Gynecologist, Obstetrician, Neonatologist, Infertility Specialist, Reproductive Endocrinologist, Midwifery, Urogynecology, Emmenologist, Infectious Disease Specialist. For Males: Urologist, Dermatologist, Infectious Disease Specialist

Also Known As:

N/A

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example. 
  • THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), or beta-blockers (propranolol, theophylline, warfarin).  Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
  • Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

CBD Interaction with Pharmaceutical Drugs

  • CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
  • Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg (0.001mg/kg to 0.005mg/kg)
  • THC low dose:  0.5 mg to 5 mg (0.006mg/kg to 0.06mg/kg)
  • THC medium dose:  6 mg to 20 mg (0.08mg/kg to 0.27mg/kg)
  • THC high dose:  21 mg to 50+ mg (0.28mg/kg to 0.67mg/kg)
Formula for converting a set dose into mg/kg considerations: mg ÷ kg = mg/kg
(sample conversion calculated on a person weighing 75kg)

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg (0.005mg/kg to 0.25mg/kg)
  • CBD medium dose: 20 mg to 99 mg (0.26mg/kg to 1.32mg/kg)
  • CBD high dose:  100 mg to 800+ mg (1.33mg/kg to 10.7mg/kg)
  • (upper limits tested ~1,500mg)
Formula for converting a set dose into mg/kg considerations: mg ÷ kg = mg/kg
(sample conversion calculated on a person weighing 75kg)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.